

Claim 17 (withdrawn) The composition of claim 1, wherein, in said core solution, said polyanionic polymers are pentasodium tripolyphosphate and kappa (iota)-carrageenan, said salt is sodium chloride, said polynucleotide is a gene and said crosslinking agent is dextran polyaldehyde; and

wherein, in said corona solution, said polycations are chitosan glutamate and F-68, said cations are Na<sup>+</sup> ~~sodium chloride~~ and/or Ca<sup>2+</sup> ~~calcium chloride~~ and said targeting conjugate is a dextran-conjugated lectin or a dextran-conjugated glycan.

Claim 18 (withdrawn) The composition of claim 17, wherein, in said core solution, said polyanionic polymers are pentasodium tripolyphosphate and kappa (iota)-carrageenan, said salt is sodium chloride and said polynucleotide is a gene; and

wherein, in said corona solution, said polycations are chitosan glutamate and F-68, said cation is calcium chloride and said targeting conjugate is a dextran-conjugated lectin or a dextran-conjugated glycan.

Claim 19 (withdrawn) The composition of claim 17, wherein, in said core solution, said polyanionic polymers are pentasodium tripolyphosphate and kappa (iota)-carrageenan, said polynucleotide is a gene and said crosslinking agent is dextran polyaldehyde; and

sulfate, said salt is sodium chloride or calcium chloride, said adenoviral polynucleotide construct comprises is a gene and said crosslinking agent is dextran polyaldehyde; and

wherein, in said corona solution, said polycations are spermine hydrochloride, PMCG hydrochloride and F-68, said cation is  $\text{Ca}^{2+}$  and said targeting conjugate is a dextran-conjugated lectin or a dextran-conjugated glycan.

Claim 15 (currently amended) The composition of claim 14, wherein, in said core solution, said polyanionic polymers are sodium alginate and cellulose sulfate, said salt is sodium chloride and said adenoviral polynucleotide construct comprises is a gene; and

wherein, in said corona solution, said polycations are spermine hydrochloride, PMCG hydrochloride and F-68, said cation is  $\text{Ca}^{2+}$  and said targeting conjugate is a dextran-conjugated lectin or a dextran-conjugated glycan.

Claim 16 (currently amended) The composition of claim 14, wherein, in said core solution, said polyanionic polymers are sodium alginate and cellulose sulfate, said salt is sodium chloride and said adenoviral polynucleotide construct comprises is a gene; and

wherein, in said corona solution, said polycations are spermine hydrochloride, PMCG hydrochloride and F-68 and said cation is  $\text{Ca}^{2+}$ .

Claim 9 (original) The composition of claim 1, wherein said gene is a gene expressing an angiogenic growth factor.

Claim 10 (withdrawn) The composition of claim 1, wherein said drug is an antiangiogenic growth factor.

Claim 11 (withdrawn) The composition of claim 1, wherein said antiangiogenic growth factor is endostatin, thrombospondin 1 or thrombospondin 2 or a combination thereof.

Claim 12 (currently amended) The composition of claim 1, wherein, in said core solution, said polyanionic polymers are sodium alginate and cellulose sulfate, said salt is sodium chloride, said adenoviral polynucleotide construct comprises is a gene and said crosslinking agent is dextran polyaldehyde.

Claim 13 (withdrawn) The composition of claim 1, wherein, in said core solution, said polyanionic polymers are pentasodium tripolyphosphate and kappa (iota)-carrageenan, said polynucleotide is a gene and said crosslinking agent is dextran polyaldehyde.

Claim 14 (currently amended) The composition of claim 1, wherein, in said core solution, said polyanionic polymers are sodium alginate and cellulose